相关实验视频
Updated: Jun 12, 2025

13:32
High Content Screening in Neurodegenerative Diseases
Published on: January 6, 2012
17.5K
针对神经退行性疾病的纳米技术驱动疗法:全面审查
Jessica López-Espinosa1,2, Peter Park1, Morgan Holcomb1
1Department of Neurosurgery & Center for Neuroregeneration, Houston, TX USA.
Therapeutic delivery
|September 19, 2024
概括
纳米医学使用纳米粒子 (NP) 来克服神经疾病中受损的血脑屏障 (BBB). 这些NP针对大脑区域,增强诊断和治疗,以获得更好的患者结果.
科学领域:
- 神经科学是一个神经科学.
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
背景情况:
- 神经系统疾病导致全球显著的发病率和死亡率.
- 神经炎症和神经退行是这些疾病的标志.
- 血脑屏障 (BBB) 功能受损在神经疾病中很常见,阻碍了治疗.
研究的目的:
- 审查纳米粒子 (NP) 用于神经疾病治疗的分类和设计.
- 探索NP属性如何影响治疗交付和疗效.
- 突出纳米医学在克服神经退行性疾病的BBB挑战方面的潜力.
主要方法:
- 将NP分为有机和无机类别进行分类.
- 分析NP的化学和物理特性.
- 在向药物递送和治疗监测中对NP应用的审查.
主要成果:
- NP特征决定了它们对药物加载,释放,组织向和清除的能力.
- 可以设计NP来绕过受损的BBB.
- 有针对性的药物输送可提高药物的生物可用性,并允许实时监测疗效.
结论:
- 纳米医学,利用NP,为治疗神经退行性疾病提供了一个有希望的策略.
- 国家疗法可以解决BBB损伤,并准炎症生物标志物.
- 这种方法有可能改善神经系统疾病的诊断,治疗和患者的治疗结果.
相关概念视频
Parkinson's Disease: Overview
495
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
495
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451

